See more : LifeSpeak Inc. (LSPKF) Income Statement Analysis – Financial Results
Complete financial analysis of Eli Lilly and Company (LLY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eli Lilly and Company, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- FB Bancorp, Inc. Common Stock (FBLA) Income Statement Analysis – Financial Results
- EFUN Technology Co.,Ltd (3523.TWO) Income Statement Analysis – Financial Results
- Himalaya Shipping Ltd. (HSHP) Income Statement Analysis – Financial Results
- Tailim Packaging Co., Ltd. (011280.KS) Income Statement Analysis – Financial Results
- Exobox Technologies Corp. (EXBX) Income Statement Analysis – Financial Results
Eli Lilly and Company (LLY)
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 34.12B | 28.54B | 28.32B | 24.54B | 22.32B | 21.49B | 22.87B | 21.22B | 19.96B | 19.62B | 23.11B | 22.60B | 24.29B | 23.08B | 21.84B | 20.38B | 18.63B | 15.69B | 14.65B | 13.86B | 12.58B | 11.08B | 11.54B | 10.86B | 10.00B | 9.24B | 8.52B | 7.35B | 6.76B | 5.71B | 6.45B | 6.17B | 5.73B | 5.19B | 4.18B | 4.07B | 3.64B | 3.72B | 3.27B |
| Cost of Revenue | 7.08B | 6.63B | 7.31B | 5.48B | 4.72B | 4.68B | 6.07B | 5.65B | 5.04B | 4.93B | 4.91B | 4.80B | 5.07B | 4.37B | 4.25B | 4.38B | 4.25B | 3.55B | 3.47B | 3.22B | 2.68B | 2.18B | 2.16B | 2.06B | 1.66B | 1.52B | 1.85B | 1.57B | 1.33B | 1.25B | 1.56B | 1.53B | 1.35B | 1.28B | 1.03B | 1.13B | 1.12B | 1.17B | 1.04B |
| Gross Profit | 27.04B | 21.91B | 21.01B | 19.06B | 17.60B | 16.81B | 16.80B | 15.57B | 14.92B | 14.68B | 18.21B | 17.81B | 19.22B | 18.71B | 17.59B | 16.00B | 14.38B | 12.14B | 11.17B | 10.63B | 9.91B | 8.90B | 9.38B | 8.81B | 8.34B | 7.71B | 6.66B | 5.77B | 5.43B | 4.46B | 4.89B | 4.64B | 4.37B | 3.92B | 3.15B | 2.94B | 2.53B | 2.55B | 2.23B |
| Gross Profit Ratio | 79.25% | 76.77% | 74.18% | 77.66% | 78.85% | 78.22% | 73.46% | 73.35% | 74.76% | 74.85% | 78.76% | 78.78% | 79.13% | 81.08% | 80.55% | 78.49% | 77.20% | 77.40% | 76.28% | 76.74% | 78.74% | 80.35% | 81.28% | 81.07% | 83.42% | 83.49% | 78.24% | 78.56% | 80.31% | 78.16% | 75.81% | 75.21% | 76.34% | 75.43% | 75.42% | 72.17% | 69.30% | 68.59% | 68.23% |
| Research & Development | 9.31B | 7.19B | 7.03B | 6.09B | 5.60B | 5.05B | 5.28B | 5.24B | 4.80B | 4.73B | 5.53B | 5.28B | 5.02B | 4.88B | 4.33B | 3.84B | 3.49B | 3.13B | 3.03B | 2.69B | 2.35B | 2.15B | 2.24B | 2.02B | 1.78B | 1.74B | 1.38B | 1.19B | 1.04B | 838.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.94B | 6.44B | 6.43B | 6.12B | 6.21B | 5.98B | 6.59B | 6.45B | 6.53B | 6.62B | 7.13B | 7.51B | 7.88B | 7.05B | 6.89B | 6.63B | 6.10B | 4.89B | 4.50B | 4.28B | 4.06B | 3.42B | 3.42B | 3.23B | 2.76B | 2.66B | 2.31B | 1.99B | 1.85B | 1.40B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 1.00B | 1.20B | 1.10B | 6.21B | 5.98B | 6.59B | 6.45B | 6.53B | 6.62B | 7.13B | 7.51B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.94B | 6.44B | 6.43B | 6.12B | 6.21B | 5.98B | 6.59B | 6.45B | 6.53B | 6.62B | 7.13B | 7.51B | 7.88B | 7.05B | 6.89B | 6.63B | 6.10B | 4.89B | 4.50B | 4.28B | 4.06B | 3.42B | 3.42B | 3.23B | 2.76B | 2.66B | 2.31B | 1.99B | 1.85B | 1.40B | 3.84B | 3.11B | 2.30B | 2.13B | 1.76B | 1.69B | 1.75B | 1.51B | 1.33B |
| Other Expenses | 0.00 | -52.10M | 112.80M | 1.50B | 611.80M | 145.60M | 110.10M | -8.30M | 174.80M | 368.30M | 63.90M | -41.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 439.70M | 490.40M | 509.80M | 543.50M | 553.70M | 432.20M | 398.30M | 368.10M | 299.50M | 247.50M | 229.30M | 204.00M | 184.30M | 177.70M | 136.20M |
| Operating Expenses | 16.72B | 13.63B | 13.46B | 12.21B | 11.81B | 11.03B | 11.87B | 11.70B | 11.33B | 11.35B | 12.66B | 12.79B | 12.90B | 11.94B | 11.22B | 10.47B | 9.58B | 8.02B | 7.52B | 6.98B | 6.41B | 5.57B | 5.65B | 5.25B | 4.98B | 4.89B | 4.21B | 3.72B | 3.45B | 2.67B | 4.24B | 3.48B | 2.60B | 2.38B | 1.98B | 1.89B | 1.93B | 1.69B | 1.47B |
| Cost & Expenses | 23.80B | 20.26B | 20.77B | 17.69B | 16.53B | 15.71B | 17.94B | 17.35B | 16.37B | 16.29B | 17.57B | 17.59B | 17.97B | 16.30B | 15.47B | 14.85B | 13.83B | 11.57B | 11.00B | 10.20B | 9.08B | 7.75B | 7.81B | 7.30B | 6.64B | 6.41B | 6.06B | 5.30B | 4.78B | 3.92B | 5.80B | 5.01B | 3.96B | 3.65B | 3.01B | 3.02B | 3.05B | 2.86B | 2.51B |
| Interest Income | 173.60M | 62.80M | 25.40M | 33.00M | 80.40M | 161.30M | 167.30M | 108.70M | 87.00M | 121.00M | 119.70M | 105.00M | 79.90M | 51.90M | 75.20M | 210.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 485.90M | 331.60M | 339.80M | 359.60M | 400.60M | 272.10M | 225.00M | 185.20M | 161.20M | 148.80M | 160.10M | 177.80M | 186.00M | 185.50M | 261.30M | 228.30M | 0.00 | 0.00 | 105.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.53B | 1.52B | 1.55B | 1.32B | 1.23B | 1.61B | 1.57B | 1.50B | 1.43B | 1.38B | 1.45B | 1.46B | 1.37B | 1.33B | 1.30B | 1.12B | 1.05B | 801.80M | 726.40M | 597.50M | 548.50M | 493.00M | 454.90M | 435.80M | 439.70M | 490.40M | 509.80M | 543.50M | 553.70M | 432.20M | 398.30M | 368.10M | 299.50M | 247.50M | 229.30M | 204.00M | 184.30M | 177.70M | 136.20M |
| EBITDA | 8.57B | 8.66B | 8.04B | 8.91B | 6.90B | 5.53B | 3.99B | 5.06B | 4.38B | 4.53B | 7.50B | 7.05B | 6.91B | 8.04B | 6.92B | 43.30M | 5.85B | 4.46B | 4.38B | 4.92B | 4.05B | 3.82B | 4.18B | 4.00B | 3.80B | 3.31B | 2.95B | 2.59B | 2.54B | 2.23B | 1.05B | 1.52B | 2.07B | 1.79B | 1.39B | 1.25B | 779.30M | 1.04B | 900.60M |
| EBITDA Ratio | 25.11% | 33.05% | 30.86% | 31.14% | 29.59% | 44.87% | 33.74% | 20.19% | 22.52% | 20.38% | 22.63% | 19.95% | 29.56% | 35.33% | 35.46% | 66.09% | 36.36% | 36.68% | 35.51% | 35.51% | 33.61% | 32.60% | 36.53% | 32.35% | 37.37% | 35.65% | 54.97% | 31.54% | 36.45% | 40.68% | 15.52% | 24.27% | 34.18% | 33.27% | 29.43% | 29.04% | 21.39% | 25.75% | 25.07% |
| Operating Income | 10.33B | 7.13B | 6.36B | 6.06B | 4.97B | 6.19B | 2.15B | 3.46B | 2.69B | 2.66B | 5.37B | 4.73B | 5.53B | 6.77B | 6.37B | 5.53B | 4.80B | 4.13B | 3.65B | 3.66B | 3.50B | 3.33B | 3.73B | 3.56B | 3.36B | 2.82B | 2.46B | 2.05B | 1.98B | 1.79B | 652.60M | 1.16B | 1.77B | 1.54B | 1.16B | 1.05B | 595.00M | 860.30M | 764.40M |
| Operating Income Ratio | 30.26% | 24.97% | 22.45% | 24.69% | 22.29% | 28.78% | 9.38% | 16.30% | 13.47% | 13.56% | 23.24% | 20.94% | 22.76% | 29.35% | 29.17% | 27.13% | 25.78% | 26.29% | 24.91% | 26.40% | 27.83% | 30.04% | 32.31% | 32.77% | 33.63% | 30.58% | 28.86% | 27.86% | 29.30% | 31.43% | 10.11% | 18.74% | 30.88% | 29.65% | 27.90% | 25.72% | 16.33% | 23.12% | 23.37% |
| Total Other Income/Expenses | -3.77B | -1.85B | -201.60M | 19.10M | 291.60M | -2.35B | -1.95B | -497.30M | -802.10M | -328.40M | 341.20M | 392.90M | -179.00M | -247.00M | -1.01B | -6.84B | -926.10M | -707.40M | -931.10M | -716.80M | -240.10M | 130.00M | -177.70M | 299.00M | -118.30M | -159.50M | 442.80M | 84.50M | -216.20M | -96.30M | 49.30M | 26.80M | 110.90M | 59.60M | 165.10M | 69.00M | 0.00 | 16.00M | 32.20M |
| Income Before Tax | 6.55B | 6.81B | 6.16B | 7.23B | 5.27B | 3.68B | 2.20B | 3.37B | 2.79B | 3.00B | 5.89B | 5.41B | 5.35B | 6.53B | 5.36B | -1.31B | 3.88B | 3.42B | 2.72B | 2.94B | 3.26B | 3.46B | 3.55B | 3.86B | 3.25B | 2.67B | 510.20M | 2.03B | 1.77B | 1.70B | 701.90M | 1.18B | 1.88B | 1.60B | 1.33B | 1.12B | 595.00M | 876.30M | 796.60M |
| Income Before Tax Ratio | 19.21% | 23.85% | 21.74% | 29.46% | 23.59% | 17.12% | 9.61% | 15.90% | 13.98% | 15.30% | 25.48% | 23.93% | 22.03% | 28.28% | 24.54% | -6.42% | 20.81% | 21.78% | 18.56% | 21.23% | 25.92% | 31.21% | 30.77% | 35.52% | 32.44% | 28.85% | 5.99% | 27.65% | 26.10% | 29.74% | 10.88% | 19.17% | 32.82% | 30.80% | 31.85% | 27.42% | 16.33% | 23.55% | 24.36% |
| Income Tax Expense | 1.31B | 561.60M | 573.80M | 1.04B | 628.00M | 529.50M | 2.40B | 636.40M | 381.60M | 609.80M | 1.20B | 1.32B | 1.00B | 1.46B | 1.03B | 764.30M | 923.80M | 755.30M | 715.90M | 1.13B | 700.90M | 749.80M | 742.70M | 800.90M | 698.70M | 568.70M | 895.30M | 507.80M | 459.00M | 513.50M | 210.80M | 354.70M | 564.50M | 471.70M | 390.40M | 354.80M | 184.50M | 318.10M | 279.00M |
| Net Income | 5.24B | 6.24B | 5.58B | 6.19B | 4.64B | 3.23B | -204.10M | 2.74B | 2.41B | 2.39B | 4.68B | 4.09B | 4.35B | 5.07B | 4.33B | -2.07B | 2.95B | 2.66B | 1.98B | 1.81B | 2.56B | 2.71B | 2.78B | 3.06B | 2.72B | 2.10B | -385.10M | 1.52B | 2.29B | 1.29B | 480.20M | 708.70M | 1.31B | 1.13B | 939.50M | 761.00M | 643.70M | 558.20M | 517.60M |
| Net Income Ratio | 15.36% | 21.88% | 19.71% | 25.24% | 20.78% | 15.04% | -0.89% | 12.90% | 12.07% | 12.19% | 20.27% | 18.09% | 17.90% | 21.97% | 19.82% | -10.17% | 15.85% | 16.97% | 13.52% | 13.06% | 20.35% | 24.45% | 24.08% | 28.15% | 27.20% | 22.71% | -4.52% | 20.74% | 33.87% | 22.52% | 7.44% | 11.49% | 22.96% | 21.71% | 22.50% | 18.70% | 17.67% | 15.00% | 15.83% |
| EPS | 5.80 | 6.93 | 6.15 | 6.82 | 4.98 | 3.14 | -0.19 | 2.59 | 2.27 | 2.23 | 4.33 | 3.67 | 3.90 | 4.58 | 3.94 | -1.89 | 2.71 | 2.45 | 1.82 | 1.67 | 2.38 | 2.51 | 2.58 | 2.83 | 2.50 | 1.91 | -0.35 | 1.39 | 2.02 | 1.11 | 0.40 | 0.61 | 1.13 | 0.98 | 0.80 | 0.67 | 0.56 | 0.51 | 0.47 |
| EPS Diluted | 5.80 | 6.90 | 6.12 | 6.79 | 4.96 | 3.13 | -0.19 | 2.58 | 2.26 | 2.23 | 4.32 | 3.66 | 3.90 | 4.58 | 3.94 | -1.89 | 2.71 | 2.45 | 1.81 | 1.66 | 2.37 | 2.50 | 2.55 | 2.79 | 2.46 | 1.87 | -0.34 | 1.36 | 2.02 | 1.11 | 0.40 | 0.61 | 1.13 | 0.98 | 0.80 | 0.67 | 0.56 | 0.51 | 0.47 |
| Weighted Avg Shares Out | 903.52M | 901.74M | 906.96M | 907.63M | 931.06M | 1.03B | 1.05B | 1.06B | 1.06B | 1.07B | 1.08B | 1.11B | 1.11B | 1.11B | 1.10B | 1.09B | 1.09B | 1.09B | 1.09B | 1.08B | 1.08B | 1.08B | 1.08B | 1.08B | 1.09B | 1.10B | 1.10B | 1.09B | 1.14B | 1.16B | 1.20B | 1.16B | 1.16B | 1.15B | 1.17B | 1.14B | 1.15B | 1.09B | 1.10B |
| Weighted Avg Shares Out (Dil) | 903.28M | 904.62M | 911.68M | 912.51M | 935.68M | 1.03B | 1.05B | 1.06B | 1.07B | 1.07B | 1.08B | 1.12B | 1.11B | 1.11B | 1.10B | 1.09B | 1.09B | 1.09B | 1.09B | 1.09B | 1.08B | 1.08B | 1.09B | 1.10B | 1.11B | 1.12B | 1.13B | 1.12B | 1.18B | 1.17B | 1.20B | 1.16B | 1.16B | 1.15B | 1.17B | 1.14B | 1.15B | 1.09B | 1.10B |
Eli Lilly to Invest $3B in Wisconsin Plant to Meet Obesity Drug Demand
Per Lilly, this is its single-largest manufacturing investment in the country outside its home state. It plans to start construction on the expansion next year.
How to Play LLY Stock as Zepbound Beats NVO's Wegovy in Obesity Study
The latest Zepbound data bodes well for Lilly and could help establish the drug as the new standard for obesity medications.
Eli Lilly makes $3bn US investment as demand for weight loss drugs rises
Eli Lilly and Co (NYSE:LLY) has announced a $3 billion expansion of its manufacturing plant in Kenosha County, Wisconsin, driven by increasing demand for GLP-1 receptor agonists such as the company's Mounjaro and Zepbound jabs. Construction of the expanded facility, slated to begin...
Billionaire Izzy Englander Is Buying This Obesity Drug Stock That Could Soar Nearly 20%, According to Wall Street
Most of Israel "Izzy" Englander's favorite stocks these days are technology leaders. At least that's the conclusion you'd draw based on the top holdings of the billionaire's Millennium Management hedge fund.
Eli Lilly Chief Scientific Officer explains Zepbound's weight loss advantage
Dan Skovronsky, Eli Lilly Chief Scientific Officer, joins 'Fast Money' to talk Zepbound's recent trial results and what it means for Eli Lilly's future growth.
Lilly invests $3 billion to expand Wisconsin plant as obesity drug demand soars
Eli Lilly said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant Prairie, Wisconsin earlier this year, as it scrambles to meet soaring demand for its weight-loss and diabetes drugs.
Lilly announces $3 billion expansion of its recently acquired manufacturing facility in Wisconsin
The investment will benefit millions of patients worldwide, boosting the production of the company's medicines, including those for diabetes and obesity INDIANAPOLIS , Dec. 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a $3 billion expansion...
LLY's Zepbound Outshines NVO's Wegovy in Head-to-Head Obesity Study
LLY's obesity drug, Zepbound, shows an average weight loss of 20.2%, superior to 13.7% for NVO's Wegovy in a head-to-head study.
This Healthcare Stock Is a Favorite of Billionaires. But Is It a Buy?
Just because a bunch of billionaires all own the same stock doesn't necessarily mean it's a great pick for you. On the other hand, most billionaires have become and remained billionaires for a reason.
Britain drug-cost watchdog says it will recommend Lilly obesity drug
Britain's drugs cost-effectiveness watchdog NICE said on Thursday it will recommend Eli Lilly's obesity drug Mounjaro be made available to around 220,000 people in the country via the state health system over the next three years.
Source: https://incomestatements.info
Category: Stock Reports